Geron Corporation
GERN
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of lowā¦ read more
Healthcare
Biotechnology
28 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.45
Price0.00%
$0.00
1Y
Price
Market Cap
$925.125m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-18374.7%
EBITDA Margin-18220.4%
Net Profit Margin-20680.3%
Free Cash Flow MarginRevenue
$164.447m
+119.4%
1y CAGR+0.7%
3y CAGR+113.1%
5y CAGREarnings
-$88.009m
-9.4%
1y CAGR-18.8%
3y CAGR-29.1%
5y CAGREPS
-$0.13
-9.4%
1y CAGR+1.4%
3y CAGR-7.0%
5y CAGRBook Value
$259.531m
$555.198m
Assets$295.667m
Liabilities$121.843m
DebtDebt to Assets
22.0%
-0.4x
Debt to EBITDAFree Cash Flow
-$178.278m
-9.6%
1y CAGR-24.8%
3y CAGR-29.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company